Neuronetics Reports Fourth Quarter and Full Year 2025 Financial and Operating Results
Neuronetics, Inc. (STIM)
Last neuronetics, inc. earnings: 3/3 06:00 am
Check Earnings Report
Company Research
Source: GlobeNewswire
Total revenue of $41.8 million in Q4 2025, up 86% as reported and 23% on an adjusted pro forma basis versus Q4 2024 Greenbrook clinic revenue of $23.5 million in Q4 2025, up 428% as reported and 37% on an adjusted pro forma basis versus Q4 2024 Continued cash management improvement, with cash provided by operations of $0.9 million in Q4 2025 Expect full year 2026 revenue of between $160 million and $166 million Dan Reuvers appointed as President and Chief Executive Officer, effective March 23, 2026; proven medical device leader with more than 30 years of experience scaling commercial healthcare businesses MALVERN, Pa., March 17, 2026 (GLOBE NEWSWIRE) -- Neuronetics, Inc., (NASDAQ: STIM) (the “Company” or “Neuronetics”) a vertically integrated, commercial stage, medical technology and healthcare company with a strategic vision of transforming the lives of patients whenever and wherever they need help, with the leading neurohealth therapies in the world, today announced its finan
Show less
Read more
Impact Snapshot
Event Time:
STIM
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
STIM alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
STIM alerts
High impacting Neuronetics, Inc. news events
Weekly update
A roundup of the hottest topics
STIM
News
- Neuronetics (STIM) had its price target lowered by Canaccord Genuity Group Inc. from $7.00 to $3.00. They now have a "buy" rating on the stock.MarketBeat
- Neuronetics, Inc. (STIM) Q4 2025 Earnings Call Transcript [Seeking Alpha]Seeking Alpha
- Neuronetics outlines >9% 2026 revenue growth target while piloting new TMS models and preparing for Compass therapy launch [Seeking Alpha]Seeking Alpha
- Neuronetics, Inc. Q4 2025 Earnings Call Summary [Yahoo! Finance]Yahoo! Finance
- Neuronetics (STIM) Q4 2025 Earnings Transcript [Yahoo! Finance]Yahoo! Finance
STIM
Earnings
- 3/17/26 - Beat
STIM
Analyst Actions
- 3/19/26 - Canaccord Genuity
STIM
Sec Filings
- 3/20/26 - Form 4
- 3/19/26 - Form 144
- 3/19/26 - Form 144
- STIM's page on the SEC website